CD86 and glioma: JWH133 treatment also significantly increased the mRNA level of M2 subtype markers CD206, Arg1, and Ym1 and decreased the mRNA level of M1 subtype markers CD68, CD86, and iNOS in the tissues around glioma, in vivo (*P < 0.05 and **P < 0.01 vs. Vehicle; Figure 1E).